Cargando…

PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas

The HER receptors are of therapeutic and prognostic significance in breast cancer, and their function is modulated by cytoplasmic tyrosine kinases like PTK6 (brk). We performed a retrospective study on archival breast cancer samples from patients with long follow-up and compared the protein expressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aubele, M, Auer, G, Walch, A K, Munro, A, Atkinson, M J, Braselmann, H, Fornander, T, Bartlett, J M S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360069/ https://www.ncbi.nlm.nih.gov/pubmed/17299391 http://dx.doi.org/10.1038/sj.bjc.6603613

Ejemplares similares

Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients
por: Aubele, M, et al.
Publicado: (2008)

In situ quantification of HER2–protein tyrosine kinase 6 (PTK6) protein–protein complexes in paraffin sections from breast cancer tissues
por: Aubele, M, et al.
Publicado: (2010)

MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion
por: Falkenberg, N, et al.
Publicado: (2013)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer
por: Mori, N, et al.
Publicado: (2010)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Detection of HER2 amplification in circulating free DNA in patients with breast cancer
por: Page, K, et al.
Publicado: (2011)

A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer
por: Bussolati, G, et al.
Publicado: (2005)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches
por: Lehmann-Che, J, et al.
Publicado: (2011)

Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer
por: Ettl, T, et al.
Publicado: (2012)

MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells
por: Ponnusamy, M P, et al.
Publicado: (2008)

EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer
por: Soysal, S D, et al.
Publicado: (2013)

A positive role for PEA3 in HER2-mediated breast tumour progression
por: Myers, E, et al.
Publicado: (2006)

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma
por: Mimura, K, et al.
Publicado: (2005)

Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial
por: Bartlett, J M S, et al.
Publicado: (2013)

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
por: Pils, D, et al.
Publicado: (2007)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk
por: Katz, E, et al.
Publicado: (2010)

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
por: Arnould, L, et al.
Publicado: (2006)

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
por: Flores, L M, et al.
Publicado: (2010)

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
por: de Graeff, P, et al.
Publicado: (2009)

Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma
por: Maruyama, T, et al.
Publicado: (2010)

RET rearrangements in post-Chernobyl papillary thyroid carcinomas with a short latency analysed by interphase FISH
por: Unger, K, et al.
Publicado: (2006)

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer
por: Ihnen, M, et al.
Publicado: (2010)

Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
por: Wilson, G R, et al.
Publicado: (2006)

Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification
por: Betof, A S, et al.
Publicado: (2012)

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
por: Zidan, J, et al.
Publicado: (2005)

Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma
por: Keller, J, et al.
Publicado: (2013)

Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
por: Fujii, Takeo, et al.
Publicado: (2017)

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
por: Martin, V, et al.
Publicado: (2013)

Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival
por: Kuang, B-H, et al.
Publicado: (2013)

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
por: Rakovitch, E, et al.
Publicado: (2012)

The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma
por: Pinato, D J, et al.
Publicado: (2013)

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
por: Bellone, S, et al.
Publicado: (2012)

Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking
por: Sugio, K, et al.
Publicado: (2006)

Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells
por: Kaistha, B P, et al.
Publicado: (2014)

Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients
por: McCall, P, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_0qsqj07ce3sechs4uf6a231k53